Drug intelligence / Profile preview

mitomycin-c + cisplatin

Development stage
Phase 3
Lead developer
Kyowa Kirin
Modality
Small Molecules
Administration
Intravenous
01

Overview

Mitomycin-c + cisplatin is a combination chemotherapy regimen consisting of two antineoplastic agents—mitomycin-C and cisplatin. Mitomycin-C is an alkylating agent that cross-links DNA, inhibiting DNA synthesis and leading to cell death. Cisplatin is a platinum-based chemotherapeutic that forms DNA adducts and cross-links, also disrupting DNA replication and transcription. This combination has demonstrated antitumor activity in several malignancies, including advanced or recurrent squamous-cell carcinoma of the uterine cervix[1], malignant mesothelioma[2], and has been studied in other solid tumors such as non-small cell lung cancer (NSCLC)[5]. The regimen is generally administered intravenously on a cyclical basis and can be given on an outpatient basis. Toxicities are primarily gastrointestinal and hematological but are considered manageable.

Other names
mitomycin C + cisplatinmitomycin + cisplatinMMC + cisplatin
02

Targets

DNA

Beyond the preview

Go deeper on mitomycin-c + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitomycin-c + cisplatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call